Sézary's disease
Template:DiseaseDisorder infobox
WikiDoc Resources for Sézary's disease |
Articles |
---|
Most recent articles on Sézary's disease Most cited articles on Sézary's disease |
Media |
Powerpoint slides on Sézary's disease |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Sézary's disease at Clinical Trials.gov Trial results on Sézary's disease Clinical Trials on Sézary's disease at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Sézary's disease NICE Guidance on Sézary's disease
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Sézary's disease Discussion groups on Sézary's disease Patient Handouts on Sézary's disease Directions to Hospitals Treating Sézary's disease Risk calculators and risk factors for Sézary's disease
|
Healthcare Provider Resources |
Causes & Risk Factors for Sézary's disease |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Sézary's disease (or "Sézary syndrome") is a type of cutaneous lymphoma characterized by Albert Sézary. [1]
"Sézary's cells" are T-cells that have pathological quantities of mucopolysaccharides.
Sézary's disease is sometimes considered a late stage of mycosis fungoides.
General
Sezary syndrome and Mycosis Fungoides are T-cell lymphomas whose primary manifestation is in the skin.
Etiology
HTLV has thought to have been associated with both of the above cutaneous mycoses.
Symptoms
The hallmark symptoms for Sézary's disease are
- Generalized erythroderma
- Lymphadenopathy
- Atypical T-cells ("Sezary cells") in the peripheral blood.
Treatment
Vorinostat (Zolinza®) is a second-line drug for CTCL. Treatments are often used in combination.